In COVID-19, a retrospective analysis of tocilizumab therapy in relation to baseline IL-6 levels showed a significant reduction in mortality (from 36% to 16%) in patients with baseline IL-6 levels above 30 pg/ml but no reduction in mortality in IL-6 below 30 pg/ml [6]. This evidence concerns the gene IL6 and COVID-19.